NCT02255266已完成不适用
Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in Daily Practice
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 1,788
- 试验地点
- 1
- 主要终点
- Frequency of patients achieving HbA1c reduction of at least 1%-point
研究概览
简要总结
This study is conducted in Europe. The aim of this study is to investigate Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in daily Practice.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects of age above 18 years as per Victoza® SmPC par.4.2 and 5.1 diagnosed with type 2 diabetes receiving the first prescription of liraglutide in 2011
排除标准
- •None. Available data from all eligible patients for each center, will be included
研究组 & 干预措施
A
干预措施: liraglutide (Drug)
结局指标
主要结局
Frequency of patients achieving HbA1c reduction of at least 1%-point
时间窗: Week 0, week 52
次要结局
- Frequency of patients achieving HbA1c reduction of at least 1%-point(After 4 and 24 months of treatment)
- Change in HbA1c (Glycosylated haemoglobin))(Week 0, week 104)
- Percentage of treatment discontinuation for any reason(At 4, 12 and 24 months)
- Changes in blood pressure and lipid profile(Week 0, week 104)
- Change in body weight(Week 0, week 104)
- Frequency of patients achieving HbA1c target (<=7%)(After 4, 12 and 24 months)
- Frequency of patients achieving a body weight reduction of at least 3%(After 4, 12 and 24 months)
- Frequency of patients achieving the composite endpoint consisting in: HbA1c reduction of at least 1%-point and body weight reduction of at least 3%(After 4, 12 and 24 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Treatment of Diabetic Neuropathy With LiraglutideType 1 Diabetes MellitusDiabetes Mellitus, Type 1NCT02138045Aalborg University Hospital39
已完成
1 期
A Trial to Assess the Effect of Liraglutide on Blood Triglyceride (Fat) Levels After a Meal in Type 2 DiabeticsDiabetes Mellitus, Type 2DiabetesNCT00993304Novo Nordisk A/S20
已完成
4 期
Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2NCT01973231Novo Nordisk A/S404
已完成
2 期
Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2NCT00154401Novo Nordisk A/S177
已完成
3 期
Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - MaintenanceMetabolism and Nutrition DisorderObesityNCT00781937Novo Nordisk A/S422